Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Arvinas Inc (ARVN)

Arvinas Inc (ARVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,836,011
  • Shares Outstanding, K 68,713
  • Annual Sales, $ 78,500 K
  • Annual Income, $ -367,300 K
  • EBIT $ -357 M
  • EBITDA $ -366 M
  • 60-Month Beta 1.96
  • Price/Sales 22.74
  • Price/Cash Flow N/A
  • Price/Book 3.05

Options Overview Details

View History
  • Implied Volatility 96.39% ( +2.09%)
  • Historical Volatility 68.52%
  • IV Percentile 98%
  • IV Rank 74.18%
  • IV High 109.09% on 08/05/24
  • IV Low 59.89% on 05/01/24
  • Put/Call Vol Ratio 0.96
  • Today's Volume 47
  • Volume Avg (30-Day) 362
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 7,750
  • Open Int (30-Day) 7,044

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.07
  • Number of Estimates 11
  • High Estimate -0.22
  • Low Estimate -1.87
  • Prior Year -2.53
  • Growth Rate Est. (year over year) +57.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.17 +21.49%
on 11/20/24
28.83 -10.79%
on 11/06/24
-1.18 (-4.39%)
since 11/01/24
3-Month
21.17 +21.49%
on 11/20/24
29.61 -13.14%
on 10/30/24
-0.44 (-1.68%)
since 08/30/24
52-Week
21.17 +21.49%
on 11/20/24
53.08 -51.54%
on 02/16/24
+2.12 (+8.98%)
since 12/01/23

Most Recent Stories

More News
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

ARVN : 25.72 (-3.74%)
Arvinas, Inc. to Present Clinical Data for Vepdegestrant at the 2024 San Antonio Breast Cancer Symposium

Arvinas will present three vepdegestrant posters at SABCS 2024, detailing its use in ER+/HER2- breast cancer.Quiver AI SummaryArvinas, Inc. announced the presentation of three posters detailing clinical...

ARVN : 25.72 (-3.74%)
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

ARVN : 25.72 (-3.74%)
Arvinas to Participate in Upcoming Investor Conferences

ARVN : 25.72 (-3.74%)
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

ARVN : 25.72 (-3.74%)
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

ARVN : 25.72 (-3.74%)
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

ARVN : 25.72 (-3.74%)
OSI: Fiscal Q4 Earnings Snapshot

OSI: Fiscal Q4 Earnings Snapshot

ARVN : 25.72 (-3.74%)
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response

/CNW/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In...

ONCY : 0.9097 (-2.20%)
ICCM : 0.8140 (-2.19%)
ATOS : 1.2700 (-2.31%)
ARVN : 25.72 (-3.74%)
PFE : 25.82 (-1.49%)
ONC.TO : 1.27 (-3.79%)
Biotech Firms Intensify Efforts as Breast Cancer Strikes Younger Patients at Alarming Rate

USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In particular, a surge in cases of breast cancer is...

ONCY : 0.9097 (-2.20%)
ONC.TO : 1.27 (-3.79%)
ICCM : 0.8140 (-2.19%)
ATOS : 1.2700 (-2.31%)
ARVN : 25.72 (-3.74%)
PFE : 25.82 (-1.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.

See More

Key Turning Points

3rd Resistance Point 27.75
2nd Resistance Point 27.35
1st Resistance Point 26.53
Last Price 25.72
1st Support Level 25.31
2nd Support Level 24.91
3rd Support Level 24.09

See More

52-Week High 53.08
Fibonacci 61.8% 40.89
Fibonacci 50% 37.13
Fibonacci 38.2% 33.36
Last Price 25.72
52-Week Low 21.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar